Immune Response receives delisting notice, will appeal

New York, Sept. 30 - Immune Response Corp. said it received a notice that it does not meet the standards for continued listing on the Nasdaq Capital Market - but the company said it will appeal, staying the delisting until its case is heard.

The Carlsbad, Calif., biopharmaceutical company received the notice because the value of its listed securities is below the $35 million threshold required by the Nasdaq Capital Market, formerly the Nasdaq Small Cap Market.

A hearing on Immune Response's appeal is expected in four to six weeks.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.